MicroRNAs as Biomarkers for Clinical Features of Lung CancerRoland Hubaux*, Daiana D Becker-Santos, Katey S. S. Enfield, Stephen Lam, Wan L Lam and Victor D. Martinez
Department of Integrative Oncology, British Columbia Cancer Research Centre, 675 West 10th Avenue, V5Z 1L3 Vancouver, B.C, Canada
- *Corresponding Author:
- Roland Hubaux
Department of Integrative Oncology
BC Cancer Research Centre, 675 West 10th Avenue
British Columbia, Canada, V5Z 1L3
E-mail: [email protected]
Received date: February 16, 2012; Accepted date: March 19, 2012; Published date: March 21, 2012
Citation: Hubaux R, Becker-Santos DD, Enfield KSS, Lam S, Lam WL, et al. (2012) MicroRNAs as Biomarkers for Clinical Features of Lung Cancer. Metabolomics 2:108. doi:10.4172/2153-0769.1000108
Copyright: © 2012 Hubaux R, et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
Each year about 1.4 million people die from lung cancer worldwide. Despite efforts in prevention, diagnosis and treatment, survival rate remains poor for this disease. This unfortunate situation is largely due to the fact that a high proportion of cases are diagnosed at advanced stages, highlighting the great need for identifying new biomarkers in order to improve early diagnosis and treatment. Recent studies on microRNAs have not only shed light on their involvement in tumor development and progression, but also suggested their potential utility as biomarkers for subtype diagnostics, staging and prediction of treatment response. This review article summarizes the impact of microRNAs on lung cancer biology, and highlights their role in the detection and classification of lung cancer as well as direct targets for drug development.